DS
ENGNW icon

David Shaw’s enGene Therapeutics Warrants ENGNW Stock Holding History

David Shaw’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.3K Hold
104,622
– – ﹤0.01% 4729
2026
Q1 		$275K Hold
104,622
– – ﹤0.01% 4110
2025
Q4 		$314K Hold
104,622
– – ﹤0.01% 4124
2025
Q3 		$75.3K Hold
104,622
– – ﹤0.01% 4380
2025
Q2 		$70.1K Hold
104,622
– – ﹤0.01% 4151
2025
Q1 		$67K Hold
104,622
– – ﹤0.01% 4046
2024
Q4 		$88.9K Hold
104,622
– – ﹤0.01% 4176
2024
Q3 		$209K Hold
104,622
– – ﹤0.01% 4136
2024
Q2 		$145K Hold
104,622
– – ﹤0.01% 4128
2024
Q1 		$544K Sell
104,622
-100
-0.1% -$305 ﹤0.01% 3440
2023
Q4 		$89K Buy
+104,722
New +$80.5K ﹤0.01% 3987

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

David Shaw's ENGNW Position: Q2 2026 in Review

David Shaw held its enGene Therapeutics Warrants (ENGNW) position steady in Q2 2026 at 104,622 shares worth $30.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4729.

David Shaw first reported a position in ENGNW in Q4 2023 and has held it in 11 quarters since. The position peaked at $544K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • David Shaw held 104,622 shares of enGene Therapeutics Warrants worth $30.3K as of Q2 2026.
  • David Shaw left its enGene Therapeutics Warrants share count unchanged in Q2 2026.
  • enGene Therapeutics Warrants made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4729 holding.
  • David Shaw first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 11 quarters since.
  • David Shaw's enGene Therapeutics Warrants position peaked at $544K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.